NIH-Funded Research Centers Launched with Focus on Alzheimer Drug Development
October 2nd 2019The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.
Read More
Network of Research Centers Created for Development of Longer-Lasting Influenza Vaccines
October 1st 2019The National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the National Institute of Health, has developed the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program.
Read More
Fast Track Designation Granted for Relapsed/Refractory Myelofibrosis Treatment
October 1st 2019Officials from the FDA have granted Geron Corporation’s imetelstat fast track designation for adult patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.
Read More
Generic Fulvestrant Injection Launched for Breast Cancer Monotherapy in Post-Menopausal Women
October 1st 2019Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.
Read More
Canagliflozin Approved by FDA for Diabetes-Related Kidney Disease
September 30th 2019Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).
Read More
Finding Modern Medicines in Ancient Cultures
September 29th 2019Along with her B.S. in pharmacy from UNC-Chapel Hill, author Amy Greeson’s education has included some much more unique experiences. She’s been to Belize to study native therapies, studied in the Amazon with a local medicine man and woman, and learned from traditional healers in Mexico.
Read More
FDA Approves Injection for Children with GPA, MPA
September 28th 2019The FDA has given the green light to rituximab (Rituxan) injection for the treatment of granulomatosis with polyangiitus (GPA) and microscopic polyangiitis (MPA) in children age 2 and older in combination with glucocorticoids. The application was approved under priority review and with orphan designation.
Read More